Why the study?
Do combined anti-IL-3 and anti-GM-CSF antibodies prevent experimental cerebral malaria in Plasmodium berghei ANKA-infected mice?
Do combined anti-IL-3 and anti-GM-CSF antibodies prevent experimental cerebral malaria in Plasmodium berghei ANKA-infected mice?
Combined blockade of IL-3 and GM-CSF prevents experimental cerebral malaria in mice by inhibiting TNF release and macrophage accumulation.
Answers are grounded in this paper and cite their sources.
Supports dual IL-3/GM-CSF blockade in experimental cerebral malaria; human translation remains untested.
IL-3 and granulocyte/macrophage colony stimulating factor (GM-CSF) are two cytokines released by activated T lymphocytes that stimulate the growth and differentiation of various hematopoietic cell lines, among which are macrophages. It has been shown that TNF/cachectin, another cytokine that is released mostly by activated macrophages, plays a central role in experimental cerebral malaria (CM), an acute and lethal neurological syndrome induced by Plasmodium berghei ANKA infection in CBA mice. Since CM requires functional CD4+ T lymphocytes to occur, we explored, by injecting rabbit antibodies to murine rIL-3 and/or GM-CSF, whether these cytokines are intermediates in the marked TNF release leading to CM. Treatment of infected mice with each antibody separately had no protective effect. In contrast, when both anti-rGM-CSF and anti-rIL-3 antibodies were injected together; (a) the occurrence of neurological syndrome was prevented in 90% of the cases; (b) the rise in serum TNF was prevented; and (c) macrophage accumulation in the spleen was significantly reduced. Murine CM appears to involve a cytokine cascade in which IL-3 and GM-CSF lead to the accumulation of TNF-releasing macrophages in vivo.
No takes yet. Share an insight, caveat, or question.
Grau et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: